Drug Approval | June 24, 2022
Rivaroxaban approved in Japan for patients with PAD after revascularisation
It´s the first trial to demonstrate the benefits of dual pathway inhibition
It´s the first trial to demonstrate the benefits of dual pathway inhibition
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
The array available for a subscription includes popular products to make menstrual hygiene a regular practice and extend further affordability to its users
Brings 25 years of global operations and supply chain experience to Piramal
Becomes first Japanese logistics company to collaborate with EMBALL’ISO, which has a proven track record in vaccine transport
Sanjay Verma of Akums Drugs & Pharmaceuticals, Manu Gupta of Cadila Pharmaceuticals, Rahul Borse of RPG Life Sciences, Krishna Sai T of Biocon and Amit Saluja of NASSCOM are speakers
This is the first Agilent lab to receive the My Green Lab Certification and plans are under way to certify additional labs.
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
Indira IVF has established technological supremacy as the key differentiator, delivering industry leading success rate
Subscribe To Our Newsletter & Stay Updated
